BIMZELX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug BIMZELX contains one active pharmaceutical ingredient (API):

1	Bimekizumab UNII 09495UIM6V - BIMEKIZUMAB
	Bimekizumab is a humanised IgG1/κ monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis.
	Read more about Bimekizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BIMZELX Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC21		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02525267, 02525275
EE	Ravimiamet	1860858, 1860869, 1860870, 1860881, 1860892, 1860904, 1860915, 1860926
ES	Centro de información online de medicamentos de la AEMPS	1211575002, 1211575006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	142295
FR	Base de données publique des médicaments	62412256, 68708415
IL	מִשְׂרַד הַבְּרִיאוּת	9195
IT	Agenzia del Farmaco	049693017, 049693029, 049693031, 049693043, 049693056, 049693068, 049693070, 049693082
JP	医薬品医療機器総合機構	3999464G1020, 3999464G2026
LT	Valstybinė vaistų kontrolės tarnyba	1093225, 1093226, 1093227, 1093228, 1093229, 1093230, 1093231, 1093232
PL	Rejestru Produktów Leczniczych	100457660, 100457678
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68773001
US	FDA, National Drug Code	50474-780, 50474-781